Matched-adjusted comparison of liso-cel versus axi-cel for the second-line treatment of R/R LBCL

Matching-adjusted indirect comparison of liso-cel vs axi-cel in the 2L treatment of R/R LBCLПодробнее

The value of axi-cel as a second-line treatment in R/R LBCLПодробнее

Primary analysis of the TRANSFORM study: liso-cel vs SOC as second-line treatment for R/R LBCLПодробнее

TRANSFORM: liso-cel versus standard of care as second-line therapy for R/R LBCLПодробнее

Choosing between tisa-cel, liso-cel & axi-cel in LBCLПодробнее

Rationale of TRANSFORM: liso-cel vs SOC in patients with high-risk R/R NHLПодробнее

Comparing axi-cel and tisa-cel in B-cell lymphomasПодробнее

Is Axi-Cel in Second Line the New Standard in Aggressive B-Cell Lymphoma? - Medpage TodayПодробнее

Matching-adjusted indirect comparisons of acalabrutinib vs ibrutinib in treatment-naïve CLLПодробнее

Where Does Axi-Cel Fit in Large B-Cell Lymphoma Treatment?Подробнее

Standard-of-care setting results of axi-cel in R/R large B-cell lymphomaПодробнее

Differential dynamics of response between axi-cel and tisa-cel in R/R B-cell lymphomaПодробнее

Improving second-line treatments in DLBCLПодробнее

CD58 aberrations correlate with poor response to axi-cel in LBCLПодробнее

Feasibility of outpatient CAR-T therapy for LBCLПодробнее

New standard: Combination immuno- and radiotherapy for advanced non-small cell lung cancerПодробнее

Second-Line Treatment for Follicular LymphomaПодробнее

What are the Hurdles to Using Cell of Origin in Classification to Treat DLBCL?Подробнее

What is Double Hit Lymphoma? - ICML 2019Подробнее